Preclinical Evaluation of a New Series of Albumin-Binding 177 Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics.

Prostate-specific membrane antigen (PSMA)-based low-molecular-weight agents using beta(β)-particle-emitting radiopharmaceuticals is a new treatment paradigm for patients with metastatic castration-resistant prostate cancer. Although results have been encouraging, there is a need to improve the tumor residence time of current PSMA-based radiotherapeutics. Albumin-binding moieties have been used strategically to enhance the tumor uptake and retention of existing PSMA-based investigational agents. Previously, we developed a series of PSMA-based, β-particle-emitting, low-molecular-weight compounds. From this series, 177 Lu-L1 was selected as the lead agent because of its reduced off-target radiotoxicity in preclinical studies. The ligand L1 contains a PSMA-targeting Lys-Glu urea moiety with an N-bromobenzyl substituent in the ε-amino group of Lys. Here, we structurally modified 177 Lu-L1 to improve tumor targeting using two known albumin-binding moieties, 4-(p-iodophenyl) butyric acid moiety (IPBA) and ibuprofen (IBU), and evaluated the effects of linker length and composition. Six structurally related PSMA-targeting ligands (Alb-L1–Alb-L6) were synthesized based on the structure of 177 Lu-L1. The ligands were assessed for in vitro binding affinity and were radiolabeled with 177 Lu following standard protocols. All 177 Lu-labeled analogs were studied in cell uptake and selected cell efficacy studies. In vivo pharmacokinetics were investigated by conducting tissue biodistribution studies for 177 Lu-Alb-L2– 177 Lu-Alb-L6 (2 h, 24 h, 72 h, and 192 h) in male NSG mice bearing human PSMA+ PC3 PIP and PSMA− PC3 flu xenografts. Preliminary therapeutic ratios of the agents were estimated from the area under the curve (AUC 0-192h ) of the tumors, blood, and kidney uptake values. Compounds were obtained in >98% radiochemical yields and >99% purity. PSMA inhibition constants (K i s) of the ligands were in the ≤10 nM range. The long-linker-based agents, 177 Lu-Alb-L4 and 177 Lu-Alb-L5, displayed significantly higher tumor uptake and retention (p < 0.001) than the short-linker-bearing 177 Lu-Alb-L2 and 177 Lu-Alb-L3 and a long polyethylene glycol (PEG) linker-bearing agent, 177 Lu-Alb-L6. The area under the curve (AUC 0-192h ) of the PSMA+ PC3 PIP tumor uptake of 177 Lu-Alb-L4 and 177 Lu-Alb-L5 were >4-fold higher than 177 Lu-Alb-L2, 177 Lu-Alb-L3, and 177 Lu-Alb-L6, respectively. Also, the PSMA+ PIP tumor uptake (AUC 0-192h ) of 177 Lu-Alb-L2 and 177 Lu-Alb-L3 was ~1.5-fold higher than 177 Lu-Alb-L6. However, the lowest blood AUC 0-192h and kidney AUC 0-192h were associated with 177 Lu-Alb-L6 from the series. Consequently, 177 Lu-Alb-L6 displayed the highest ratios of AUC(tumor)-to-AUC(blood) and AUC(tumor)-to-AUC(kidney) values from the series. Among the other agents, 177 Lu-Alb-L4 demonstrated a nearly similar ratio of AUC(tumor)-to-AUC(blood) as 177 Lu-Alb-L6. The tumor-to-blood ratio was the dose-limiting therapeutic ratio for all of the compounds. Conclusions: 177 Lu-Alb-L4 and 177 Lu-Alb-L6 showed high tumor uptake in PSMA+ tumors and tumor-to-blood ratios. The data suggest that linker length and composition can be modulated to generate an optimized therapeutic agent. [ABSTRACT FROM AUTHOR]

Copyright of Molecules is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)